Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel S Cooper

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Veterinary Sciences|May 24, 2024
Clinical Findings and Outcome in 30 Dogs with Presumptive or Confirmed Nerve Sheath TumorsRachel S Cooper-Khan, Alexandra N Frankovich, Craig A Thompson, et al.
Clinical and Experimental Immunology|June 19, 2021
Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapyRachel S Cooper, Aleksandra Kowalczuk, Gwen Wilkie, et al.
Journal of Leukocyte Biology|November 15, 2021
CCR7<sup>+</sup> dendritic cells sorted by binding of CCL19 show enhanced Ag-presenting capacity and antitumor potencyPaul Burgoyne, Alan J Hayes, Rachel S Cooper, et al.
Frontiers in Immunology|January 25, 2021
Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19Rachel S Cooper, Alasdair R Fraser, Linda Smith, et al.
Cytotherapy|February 17, 2021
Estimation of manufacturing development costs of cell-based therapies: a feasibility studyRenske M T Ten Ham, Julianne C Nievaart, Jarno Hoekman, et al.
Frontiers in Immunology|July 16, 2024
EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulationRachel S Cooper, Catherine Sutherland, Linda M Smith, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Veterinary Sciences|May 24, 2024
Clinical Findings and Outcome in 30 Dogs with Presumptive or Confirmed Nerve Sheath TumorsRachel S Cooper-Khan, Alexandra N Frankovich, Craig A Thompson, et al.
Clinical and Experimental Immunology|June 19, 2021
Cytometric analysis of T cell phenotype using cytokine profiling for improved manufacturing of an EBV-specific T cell therapyRachel S Cooper, Aleksandra Kowalczuk, Gwen Wilkie, et al.
Journal of Leukocyte Biology|November 15, 2021
CCR7<sup>+</sup> dendritic cells sorted by binding of CCL19 show enhanced Ag-presenting capacity and antitumor potencyPaul Burgoyne, Alan J Hayes, Rachel S Cooper, et al.
Frontiers in Immunology|January 25, 2021
Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19Rachel S Cooper, Alasdair R Fraser, Linda Smith, et al.
Cytotherapy|February 17, 2021
Estimation of manufacturing development costs of cell-based therapies: a feasibility studyRenske M T Ten Ham, Julianne C Nievaart, Jarno Hoekman, et al.
Frontiers in Immunology|July 16, 2024
EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulationRachel S Cooper, Catherine Sutherland, Linda M Smith, et al.
Pageof 1